Fisher Asset Management LLC Grows Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Fisher Asset Management LLC raised its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 20.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 452,497 shares of the biopharmaceutical company’s stock after purchasing an additional 78,145 shares during the period. Fisher Asset Management LLC’s holdings in Celldex Therapeutics were worth $11,435,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. KBC Group NV lifted its holdings in Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 495 shares in the last quarter. Point72 DIFC Ltd lifted its holdings in shares of Celldex Therapeutics by 101.7% during the 3rd quarter. Point72 DIFC Ltd now owns 14,114 shares of the biopharmaceutical company’s stock worth $480,000 after acquiring an additional 7,116 shares during the period. Creative Planning purchased a new position in shares of Celldex Therapeutics during the 3rd quarter worth about $504,000. Los Angeles Capital Management LLC lifted its holdings in shares of Celldex Therapeutics by 128.9% during the 4th quarter. Los Angeles Capital Management LLC now owns 15,421 shares of the biopharmaceutical company’s stock worth $390,000 after acquiring an additional 8,683 shares during the period. Finally, GSA Capital Partners LLP lifted its holdings in shares of Celldex Therapeutics by 191.2% during the 3rd quarter. GSA Capital Partners LLP now owns 16,114 shares of the biopharmaceutical company’s stock worth $548,000 after acquiring an additional 10,581 shares during the period.

Celldex Therapeutics Stock Performance

CLDX opened at $19.35 on Tuesday. The firm has a 50 day moving average price of $23.75 and a 200 day moving average price of $28.80. The company has a market cap of $1.28 billion, a PE ratio of -7.53 and a beta of 1.60. Celldex Therapeutics, Inc. has a 1 year low of $19.31 and a 1 year high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.02. The firm had revenue of $1.18 million during the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. On average, sell-side analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. The Goldman Sachs Group cut their price objective on shares of Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a report on Monday. UBS Group assumed coverage on shares of Celldex Therapeutics in a report on Thursday, February 13th. They set a “buy” rating and a $44.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Friday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $55.38.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.